Overview

Trial of DFP-14927 in Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Delta-Fly Pharma, Inc.